Irina Antonijevic
Director/Board Member at 4SC AG
Net worth: 97 699 $ as of 2024-04-29
Profile
Irina Antonijevic is an Independent Director at Biohaven Ltd., a Non-Executive Director at New Biohaven Pharmaceuticals, Inc., a Non-Executive Director at Verinos Pharmaceuticals GmbH, a Member-Supervisory Board at 4SC AG, and the Chief Medical Officer at EveryONE Medicines, Inc. She previously worked as the Director of Translational Research at Lundbeck Research USA, Inc. from 2005 to 2009, Director of Clinical Research at Sanofi, Inc., Medical Director of Clinical Development at CHDI Foundation, Inc. from 2009 to 2010, Director at Biohaven Pharmaceutical Holding Co. Ltd., Head of Early Development Multiple Sclerosis at Genzyme Corp.
from 2011 to 2016, Member-Supervisory Board at PAION AG from 2017 to 2022, Chief Medical Officer at vasopharm GmbH from 2016 to 2017, VP of Translational Medicine & Development at Wave Life Sciences USA, Inc. from 2018 to 2019, and Chief Medical Officer at Triplet Therapeutics, Inc. from 2019 to 2022.
She holds a doctorate degree from The University of Edinburgh, an undergraduate degree from Technische Universität München, and a doctorate degree from Max Planck Institute of Biochemistry.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIOHAVEN LTD.
0.00% | 2024-04-29 | 2,535 ( 0.00% ) | 97 699 $ | 2024-04-29 |
Irina Antonijevic active positions
| Companies | Position | Start |
|---|---|---|
| 4SC AG | Director/Board Member | 2012-08-05 |
| BIOHAVEN LTD. | Director/Board Member | 2022-09-27 |
EveryONE Medicines, Inc.
 EveryONE Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services EveryONE Medicines, Inc. delivers individualized precision therapeutics customized to the unique pathogenic genetic mutation of patients. EveryONE Medicines is based in Boston, MA. The company's goal is to provide quality of life to patients by slowing or even halting their disease. The company was founded by Julia Vitarello and Keith Flanagan. The CEO is Nessan Bermingham. | Chief Tech/Sci/R&D Officer | 2022-06-30 |
| New Biohaven Pharmaceuticals, Inc. | Director/Board Member | - |
| Verinos Pharmaceuticals GmbH | Director/Board Member | - |
Former positions of Irina Antonijevic
| Companies | Position | End |
|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | 2022-10-02 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | 2022-10-02 |
| PAION AG | Director/Board Member | 2022-01-26 |
Triplet Therapeutics, Inc.
 Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2021-12-31 |
| ░░░░ ░░░░ ░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Irina Antonijevic
| Max Planck Institute of Biochemistry | Doctorate Degree |
| The University of Edinburgh | Doctorate Degree |
| Technische Universität München | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| 4SC AG | Health Technology |
| PAION AG | Health Technology |
| BIOHAVEN LTD. | Health Technology |
| Private companies | 11 |
|---|---|
| CHDI Foundation, Inc. | |
Lundbeck Research USA, Inc.
 Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
vasopharm GmbH
 vasopharm GmbH Pharmaceuticals: MajorHealth Technology vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany. | Health Technology |
Sanofi, Inc.
 Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a company based in New York, NY. | Retail Trade |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA. | Health Services |
Wave Life Sciences USA, Inc.
 Wave Life Sciences USA, Inc. Electric UtilitiesUtilities Part of Wave Life Sciences Ltd., Wave Life Sciences USA, Inc. is a company that provides nucleic acid therapeutics. The company is based in Cambridge, MA. The company was founded in 2012 by Gregory L. Verdine, Takeshi Wada. The CEO is Paul B. Bolno. | Utilities |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
| New Biohaven Pharmaceuticals, Inc. | |
EveryONE Medicines, Inc.
EveryONE Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services EveryONE Medicines, Inc. delivers individualized precision therapeutics customized to the unique pathogenic genetic mutation of patients. EveryONE Medicines is based in Boston, MA. The company's goal is to provide quality of life to patients by slowing or even halting their disease. The company was founded by Julia Vitarello and Keith Flanagan. The CEO is Nessan Bermingham. | Commercial Services |
| Verinos Pharmaceuticals GmbH |
- Stock Market
- Insiders
- Irina Antonijevic
